CN1293877C - Neurotrophic tacrolimus analogs - Google Patents

Neurotrophic tacrolimus analogs Download PDF

Info

Publication number
CN1293877C
CN1293877C CNB018228860A CN01822886A CN1293877C CN 1293877 C CN1293877 C CN 1293877C CN B018228860 A CNB018228860 A CN B018228860A CN 01822886 A CN01822886 A CN 01822886A CN 1293877 C CN1293877 C CN 1293877C
Authority
CN
China
Prior art keywords
chemical compound
application
dysfunction
damage
neurotrophic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018228860A
Other languages
Chinese (zh)
Other versions
CN1538843A (en
Inventor
松冈信也
山路隆之
布鲁斯·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN1538843A publication Critical patent/CN1538843A/en
Application granted granted Critical
Publication of CN1293877C publication Critical patent/CN1293877C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Tacrolimus derivatives having high levels of neurotrophic activity and low levels of immunosuppresive activity. These compounds are useful as neurotrophic agents, particularly, for preventing or treating neuronal injury/dysfunction.

Description

Neurotrophic tacrolimus analogs
Background of invention
Technical field
The present invention relates to a kind of fujimycin 506 derivant with high-level neurotrophic activity and low-level immunosuppressive activity.
Background is discussed
Some macrolides compound, for example fujimycin 506 and relevant chemical compound thereof knownly are used to help prevention or treatment cerebral ischaemia (WO 94/14443).Have the specific nipecotic acid derivant of affinity with FKBP-type immunity rabphilin Rab, fujimycin 506 for example, known being used to stimulates impaired peripheral nervous growth or promotes neuronic regeneration (WO 96/40140).Some non-immunosuppressive compounds, just geldanamycin and its analog show break steroid receptor complex and the effect (WO 99/21552) that promotes nerve growth.
Summary of the invention
The present inventor finds specific tacrolimus analogs, and the chemical compound of just mentioning below (I) has fabulous neurotrophic activity, and still different with fujimycin 506 is that it does not have or have only very low immunosuppressive activity.As follows, the chemical compound (I) of comparing with fujimycin 506 has stronger neurotrophic activity, and for example, this point by the ability weighing their and increase neurite lengths promptly as can be known.Similar, the administration of chemical compound (I) shows the recovery of inducing axon regeneration and accelerator nerve extruding or spinal cord injury.And, to compare with fujimycin 506, chemical compound (I) does not have or has only very low immunosuppressive activity when these favourable neurotrophic effects of performance.
Correspondingly, the invention provides chemical compound (I) as a kind of fabulous neurotrophic agents, also is a kind of new purposes that does not have or have only the neurotrophic agents of very low immunosuppressive action simultaneously.
Further, the invention provides a kind of neurotrophic agents or compositions that contains chemical compound (I).
Further, the invention provides a kind of prevention or treatment neuronal damage/handicapped method, this method comprises to administration chemical compound (I).
Detailed Description Of The Invention
Unexpected, the present inventor has been found that chemical compound (I) can be used for improving, neurological damage or dysfunction that prevention or treatment are caused by nervous system damage or damage, degeneration or disease, however advantageously it does not have or has only very low immunosuppressive action.
Chemical compound (I) be used for the treatment of since physical damnification, nutrition disorder, ischemia, degenerative disease, malignant diseases, infectious disease cause and by the infringement that drug interaction, toxin or poisonous substance cause, degenerate or dysfunction.For example, chemical compound (I) is used for treatment by neurosurgery, peripheral nerve injury, burn, encephalomyelitis, HIV, herpes, cancer, radiotherapy, drug interaction, folic acid or vitamin B-12 shortage with by being exposed to caused neurological infringement of neurotoxin or chemical substance such as lead or dysfunction.
Correspondingly, chemical compound (I) is used for prevention or treatment neuronal damage and dysfunction, polymyositis for example, barre-Guillaian syndrome, Menetrier's disease, polyneuritis, mononeuritis, Alzheimer, parkinson, amyotrophic lateral sclerosis (ALS), hungtington's chorea, radiculopathy, (for example diabetic is neural becomes neuropathy, neuropathy that chemotherapy causes or the like), spinal cord injury, alzheimer disease, vascular dementia, multiple sclerosis, health paralysis or the like.
Chemical compound (I), i.e. the tacrolimus analogs that uses among the present invention has following chemical structural formula:
Figure C0182288600051
This chemical compound can be according to United States Patent (USP) 5376663, and the method that embodiment 29 describes prepares.About the chemical compound (I) that uses among the present invention; should be appreciated that it also has conformer and one or more stereoisomers; for example because the optical or geometric isomer that asymmetric carbon atoms or two key cause, these conformers and stereoisomer are also included within the scope of the claimed chemical compound of the present invention.
Chemical compound (I) also can exist with the form of pharmaceutically acceptable salt, derivant, solvate or prodrug, and all these is included in the scope of protection of present invention.Solvate preferably comprises a kind of hydrate and a kind of ethylate.
A kind of preferred form of chemical compound (I) is as follows:
Figure C0182288600061
Chemical compound among the present invention (I) can be with the form of pure chemical compound or with the form administration of the mixture that forms with another chemical compound or other composition (preferably a kind of pharmaceutical media or carrier).When chemical compound (I) uses with the form of a kind of pharmaceutical preparation or compositions, it can with a kind ofly be suitable for outside (partial), oral, intestinal, subcutaneous, organic or inorganic carrier, medium or excipient intravenous, muscle or parenteral applications mix.For example, it can exist with the form of solid, semisolid or fluid composition, and these compositionss comprise chemical compound (I) and one or more carriers, medium or the excipient as active component.Typical carrier, medium or excipient include, but are not limited to the conventional medicine carrier, medical science or pharmacopedics on reagent, buffer agent, dispersant, emulsifying agent and adjuvant.
Chemical compound (I) also can mix with common nontoxic be used for tablet, pill, capsule, eye drop, suppository, solution (for example saline), Emulsion, suspensoid (for example olive oil), ointment, aerosol, spray, emulsifiable paste, skin plaster, paster and other these pharmaceutically acceptable carriers that are suitable for using.
Suitable carriers comprises water, saline, dextrose solution and oil.Oil comprises animal oil, vegetable oil, artificial oil and oil product.Other useful carrier comprises glucose, lactose, Radix Acaciae senegalis, gelatin, mannitol, gelatinized corn starch, magnesium trisilicate, Pulvis Talci, corn starch, keratin, silica gel, potato starch, carbamide and other are applicable to the carrier of producing solid, semisolid or liquid absorption member.In addition, adjuvant, stabilizing agent, emulsifying agent, thickening agent, coloring agent, flavoring agent also can use.
Chemical compound (I) is included in the pharmaceutical composition with effective dose, and this dosage can produce the effect of wanting to specific lysis or situation.Preferably, chemical compound is included in the pharmaceutical composition with the amount that a kind of neurotrophic effect or the cell enlargement that excites nerve enough are provided.
The mammal that can utilize method of the present invention to treat comprises for example cow of herding mammal, horse, pig etc.; Domestic animal is Canis familiaris L. for example, cat, rat, mice, rabbit, hamster etc., the primate and the mankind.
The product of inclusion compound 1 or compositions preferred administration or application mode when human administration comprise injection or oral administration.
Although the treatment effective dose of chemical compound (I) or dosage are can be between each one patient different, and treatment effective dose and dosage also depends on the age and the situation of each individual patient of being treated, and the active component daily dose scope that is commonly used to treat disease is about 0.0001-1000mg, be preferably 0.001-500mg, 0.01-100mg more preferably, the average single dose of administration is about 0.001-0.01mg usually, 0.2-0.5mg, 1mg, 5mg, 10mg, 50mg, 100mg, 250mg and 500mg.The daily dose of human long-term prescription is about 0.1-30mg/kg/ day.Chemical compound (I) also can side by side, independently or sequentially have reagent neurotrophic or the nerve growth stimulating activity with other to be used together.
The mammiferous experimenter that pharmaceutical composition among the present invention can periodically need this treatment (for example, human patients), promote neuron regeneration, functional rehabilitation and excite nerve prominent growing, therefore, treat various neuro pathologys' state, these neuro pathology's states comprise peripheral nerve injury and the central nervous system injury due to (limb after blocking is transplanted for for example spinal cord injury and wound, sciatic nerve or nervus facialis pathological changes or damage) because physical damnification; Disease (for example diabetic is neural becomes); Cancer chemotherapy (for example acrylamide, paclitaxel, the neuropathy that vinblastine and amycin cause); With relevant sequela such as speaking incoherently (for example heterophemia) such as cerebral infarction, hemorrhage infraction, confusion, dyskinesia etc.; And neurological disorder, include but not limited to various peripheral nervous characteristic of diseases and neurological obstacle, include but not limited to: trigeminal neuralgia, glossopharyngeal neuralgia, bell's palsy, myasthenia gravis, amyotrophy, amyotrophic lateral sclerosis, progressive myatrophy, the amyotrophy of carrying out property oblongata sex-controlled inheritance, hernia, disruptive or sagging intervertebral disc syndrome, cervical vertebra is tetanic, plexus disorder, thoracic outlet destruction syndrome, peripheral neurophaty for example those by lead, acrylamide, γ-diketone (glue-sniffer ' the s neuropathy), Carbon bisulfide, the peripheral neurophaty that dapsone, Ticks cause, porphyria, barre-Guillaian syndrome, Alzheimer, parkinson and hungtington's chorea.
Peripheral nervous or spinal cord injury cross-section can be by giving a kind of amount of stimulating neuronal growth of mammal reagent and give peripheral nervous or for example a kind of (Osawa etc. of allograft of a kind of nerve graft of vertebroplasty, J.Neurocytol.19:833-849,1990; Buttemeyer etc., Ann.Plastic Surgery 35:396-401,1995) or a kind of artificial nerve graft (Madison and Archibald, Exp.Neurol.128:266-275,1994; Wells etc., Exp.Neurol.146:395-402,1997) and treat.A kind of acellular gap filling material is preferably used in space between the cross-section end of peripheral nervous or spinal cord, wait as collagen, methylcellulose and to fill, or with the cell that promotes nerve growth such as schwann's cell (Xu etc., J.Neurocytol.26:1-16,1997), the suspension of olfactory receptor cell and epitheca (sheathing) cell is filled.Nerve growth promoter can be included in together with these cells or acellular gap filler, or before the neural transplantation process, among or whole body administration afterwards.
Especially, chemical compound (I) is used for treating or preventing neuronic damage/dysfunction, polymyositis, barre-Guillaian syndrome, Menetrier's disease, polyneuritis, mononeuritis, Alzheimer, parkinson, amyotrophic lateral sclerosis (ALS), hungtington's chorea, radiculopathy, the neuropathy that diabetic neuropathy, chemotherapy cause, alzheimer disease, vascular dementia, multiple sclerosis, health paralysis or spinal cord injury.
Ensuing embodiment understands the present invention in more detail.Should think that these embodiment have described some aspect of the present invention or concrete condition, but have no intention to limit the scope of the invention.
Embodiment 1: utilize the processing of chemical compound (I) to increase the neurite lengths of hippocampal neuron significantly
The preparation of cell culture:
According to Banker and Cowan(Brain Research, 1977,126:397-425), embryo's hippocampal neuron gets the young Mus of comfortable embryo the 18.5th day (" E18.5 ").Briefly, take out the hippocampus, chopping, and in the 100I.U. papain, hatched 45 minutes at 37 ℃ of C, cell is suspended in the complete neuron culture medium: do not contain L-glutaminate MEM (GIBCO, Grand Island, NY), the 1.5ml/100ml culture medium (GIBCO) of the basic dulbecco minimum essential medium Dulbecco of high glucose, the 0.1ml/100ml culture medium (Hito+Tm of serum bulking agent (extender); Collaborative Research Inc, Lexington, MA), glutamine (GIBCO), 5% hyclone (GIBCO).
Cell is seeded on the coverslip that gathers L-lysine bag quilt (500 cells/coverslip).Coverslip is upside down in and wraps in advance by on the Astrocytic vessel of monolayer cortex.
The analysis of the aixs cylinder length of hippocampal neuron:
Hippocampal neuron (identifying by their specific polarity and dendron) is checked and photograph (9-12 frame/coverslip) at random in 72 hours every day, aixs cylinder (being defined as the longest projection) length is measured by the trace of taking a picture, the trace of this photograph is utilization and has a suitable software (Bioquant IV, R ﹠amp; M Biometrics, Nashville, the Houston Instrument HI-PAD digitized image tablet that IBM XT computer TN) links to each other obtains.More than three times of cyton length have only been measured.Between the data of the equal coverslip of handling (three or four every group) acquisition, do not have difference, therefore combine them.Calculating mean value also utilizes unidirectional (chemical compound (Ia) or fujimycin 506 processed group are to a untreated control group) variance analysis to come comparison, carries out Newman-Kuels then and organizes comparison test (WINKS4.62 professional version) more.
The result:
In the time of 72 hours, there is not significant difference between untreated control group and the 10nM fujimycin 506 processed group.Yet the chemical compound of 10nM concentration (Ia) treatment group is in the significant growth that has shown aspect the neurite lengths on the statistics.Result in the face Table I as follows:
Chemical compound (Ia) and fujimycin 506 are to the influence of the average neurite lengths of rat hippocampal cell culture of former generation when showing 1:72 hour
Neurite lengths (μ m)
Untreated fish group 372.3±18.23
Fujimycin 506 group (10nM) 423.4±19.50
Chemical compound (Ia) group (10nM) 502.2±23.61*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with untreated fish group
Embodiment 2: utilize the processing of chemical compound (I) to increase the average neurite lengths of SH-SYSY people neuroblast oncocyte
The preparation of SH-SYSY neuroblastoma cell culture:
SH-SYSY people neuroblast oncocyte is at 37 ℃, 7%CO 2Maintain under the condition and be added with 10% hyclone (SIGMA), in the DMEM culture medium (GIBCO) of 50I.U./ml penicillin and 50 μ g/ml streptomycins (GIBCO).Cell is laid in the six hole flat boards with 15000 cells/well and handles with 0.4 μ M A Feidi mycin (SIGMA).The 5th day, the flushing cell was also with existing or do not exist fujimycin 506 (10nM) or chemical compound (Ia) 10ng/ml nerve growth factor (NGF) (1nM) to handle (inducing projection to grow).Culture medium was changed after 96 hours, substituted with new culture medium and placed 72 hours (total time, 168 hours) again.Use double hole in all tests, data are average datas of each processed group.
The length analysis of dashing forward of SH-SYSY neuroblastoma cellular neural:
In order to analyze the length of projection, take a picture in the time of 168 hours, at random cell (20 visual field/holes).Neurite lengths is weighed by the trace of a photograph, and the trace of this photograph is utilization and has a suitable software (Bioquant IV, R ﹠amp; M Biometrics, Nashville, the Houston InstrumentHI-PAD digitized image tablet that IBM XT computer TN) links to each other obtains.Only measured the above projection of those cyton length twices.Do not have difference between the data that from equal hole of handling, obtain, therefore combine them.Calculating mean value also utilizes unidirectional (sample of sample to only handling with NGF that chemical compound (Ia) or fujimycin 506 are handled) variance analysis to come the comparison meansigma methods, carries out Newman-Kuels then and organizes comparison test (WINKS4.62 professional version) more.
The result:
The measured value of neurite projection length shows, with independent with NGF (10ng/ml) compare 168 hours time chemical compound (Ia) (1nM) and fujimycin 506 (10nM) all increased the length of axon process significantly.Yet, be higher than effect with the 10nM fujimycin 506 of NGF associating with the effect of the 1nM chemical compound (Ia) of NGF associating.
Table 2: chemical compound (Ia) and fujimycin 506 are to the influence of the average neurite lengths of SH-SYSY people neuroblast oncocyte in the time of 168 hours
Neurite lengths (μ m)
NT 94.75±3.734
NGF(10ng/ml) 198.8±8.991
Fujimycin 506 (10nM)+NGF (10ng/ml) 227.6±9.130*
Chemical compound (Ia) (1nM)+NGF (10ng/ml) 256.0±9.067*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with the NGF group
Embodiment 3: utilize the processing of chemical compound (I) to promote the functional rehabilitation of rat sciatic nerve extrusion mode
Animal and operative procedure:
Alkyl halide with 2% is anaesthetized the male Sprague-Dawley rat in 96 ages in week, exposes the sciatic nerve on right side, in the position of buttocks level nerve is pushed (60s utilizes No. 7 Dumont jeweler ' s pincers altogether) twice.Labelling is come by an aseptic 9-O stitching thread is passed epineurial sheath in the extruding position.
The preparation and the administration of chemical compound (Ia):
Chemical compound (Ia) is dissolved in comprises 30% dimethyl sulfoxine (DMSO): in the 70% brinish medium.The medium (saline that comprises 30%DMSO) of giving three the rat subcutaneous injection every day chemical compounds (Ia) of accepting the aixs cylinder microsurgical technique (1 or 5mg/kg) or equal quantities (5ml/kg).
The evaluation of behavior:
Check every day animal up to perfusion day (the 18th day).Following sxemiquantitative grade is commonly used to estimate the functional rehabilitation of animal.
0: paralysis and foot upset and toe bending are arranged when walking;
1: the ability of correct control pin and mobile toe;
2: road constantly can walk;
3: proof toe tensible when walking;
4: lift that heel is walked and show and stretch near normal toe.
The animal of ability gives partial fraction in the middle of the proof :+, 0.25; ++, 0.5; +++, 0.75.
Fixation of tissue and preparation:
Neural extruding is after 18 days, alkyl halide deep anaesthesia rat with 4%, heparinization also is used in the paraformaldehyde perfusion 10s of 4% in the 0.1M sodium phosphate buffer (pH 7.4), next be used in glutaraldehyde (1L) perfusion of 5% in the 0.1M sodium phosphate buffer (pH 7.4), fix 24 hours at 4 ℃ then.On sciatic nerve, locate to get tissue sample apart from pulverizing location aware distance (5mm).In present research, the data that from the back tibial nerve branch of supplying with musculus soleus, obtain have only been reported.Tissue is placed in the 0.1M sodium phosphate buffer (PH7.4), with fixing 2.5 hours behind 1% Osmic acid. (in the 0.1M phosphate buffer), with ethanol dehydration and be embedded in the plastics.Semithin section is installed in the 75 order lattice that thin film is supported with the dyeing of acetic acid uranium ester and lead citrate, and with JEOL 100CX electron micrograph.
Morphological analysis:
The analysis of aixs cylinder caliber is carried out on the musculus soleus nerve.The number of regenerated medullated aixs cylinder calculates with ultramicroscope.Calculation medium processed group, chemical compound (Ia) be (5mg/kg) meansigma methods and the standard deviation of processed group of processed group and chemical compound (Ia) (1mg/kg).
Statistical analysis:
For the analysis of behavior,, carry out Newman-Kuels then and organize comparison test more and come each value of comparison with the meansigma methods that unidirectional variance analysis comes comparing function to recover.As for morphological analysis,, carry out Newman-Kuels then and organize check more and come each value of comparison with the meansigma methods that unidirectional variance analysis comes comparison aixs cylinder number.
The result:
Functional rehabilitation:
Observed functional rehabilitation at 15-17 days, and the functional rehabilitation of 1mg/kg processed group rat and 5mg/kg processed group rat all than the functional rehabilitation of media processes group rat occur morning.The table 3 of face as follows.
The effect of table 3. chemical compound (Ia) in the Rats'Sciatic Nerve Injury functional rehabilitation
The mark of function
Medium (s.c.) (saline that contains 30%DMSO) Chemical compound (Ia)
1mg/kg(s.c.) 5mg/kg(s.c.)
The 15th day 1.67±0.08 2.58±0.17* 3.17±0.08*
The 16th day 1.83±0.08 2.83±0.17* 3.50±0.00*
The 17th day 2.50±0.00 3.08±0.22* 3.50±0.00*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with media pack
Electron micrograph
The morphological examination of animal was carried out at aixs cylinder microsurgery postoperative on the 18th day.
Every neural area (5,000 μ m 2) in the number of regenerated medullated aixs cylinder produce phenomenal growth, from media processes group rat 5.5 ± 2.7 (meansigma methods ± SEM) to 1 and 5mg/kg processed group rat 19 ± 2.4 and 20 ± 2.9, (P＜0.05) separately.Face table 4 as follows.
Table 4: chemical compound (Ia) when rat sciatic nerve is pulverized back 18 days to the every neural area of flatfish muscular nerve (5,000 μ m 2) the influence of regenerated myelinated axon number
Medium (s.c.) (saline that contains 30%DMSO) Chemical compound (Ia)
1mg/kg(s.c.) 5mg/kg(s.c.)
Regenerated medullated aixs cylinder 5.5±2.7 19±2.4* 20±2.9*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with media pack
Embodiment 4: promoted functional rehabilitation in the Spinal Cord Injury in Rats model with the processing of chemical compound (I)
(1) method
Animal and surgical procedure
With big male Sprague-Dawley rat of 28 six of 2% alkyl halide anesthesia week, carry out laminectomy and carry out spinal cord hemisection infringement in spinal cord T10/T11 level at T10/T11.
The preparation and the administration of chemical compound (Ia)
Chemical compound (Ia) is dissolved in comprises 30% dimethyl sulfoxine (DMSO): in the 70% brinish medium.In back 7 week of operation the rat of spinal cord injury get an injection under the skin every day chemical compound (Ia) (2mg/kg) or the medium of equal volume (saline that contains 30%DMSO) (5ml/kg).
The evaluation of functional rehabilitation
Utilize an improved Tarlov/Klinger grade, the test of narrow crossbeam and footprint test 2 weeks Function of Evaluation recovery after infringement.
A. improved Tarlov/Klinge grade
Allow rat in the open place of a slice free movable 1 minute and with below the grade 0-6 that provides evaluate.
0: impaired hind leg is motion not;
1: impaired hind leg does not almost have perceptible motion;
2: but impaired hind leg joint (buttocks, knee joint or ankle) has active motion is inharmonious, can not supported weight;
3: impaired hind leg has alternative walking and propulsive motion is arranged, can not supported weight;
4: but impaired hind leg supported weight;
5: have only small insufficient walking;
6: normal walking
B. narrow crossbeam test
The wooden crossbeam that rat successively decreases at width (1.5m is long) is gone up test, and width is respectively 7.7cm, 4.7cm, 2.7cm and 1.7cm.Allow rat on batten, walk, write down they can not slip with the narrowest batten of at least two track travels.
0: can not on any one crossbeam, walk;
1: can on the wide crossbeam of 7.7cm, walk;
2: can on the wide crossbeam of 4.7cm, walk;
3: can on the wide crossbeam of 2.7cm, walk;
4: can on the wide crossbeam of 1.7cm, walk;
C. footprint test
The hind leg of rat is stained with ink and footprint is imprinted on the paper that covers on the narrow runway that 60cm is long and 7.5cm is wide.A series of at least 6 successives are used to determine 5-point footprint score value usually.
0: the walking or the hind leg of the dorsal part that continues drag, for example, and invisible footprint
1: the toe seal that at least 3 toes in visible at least 3 footprints are arranged
2: compare the outer or internal rotation of demonstration with its baseline value more than the foot of twice value
3: the marking that except the foot rotation, does not have toe to drag
4: in showing or the external rotation marking (less than the baseline value angle of twice), but as seen more than one heel seal
5: do not see the heel seal
Statistical analysis
For the analysis of behavior,, carry out Newman-Kuels then and organize comparison test more and come each value of comparison with the meansigma methods that unidirectional variance analysis comes each function test score value of comparison.
The result
Functional rehabilitation
Utilize improved Tarlov/Klinger grade (table 5), crossbeam walking test (table 6) and footprint test (table 7) are carried out all three functional rehabilitations and are measured.In improved Tarlov/Klinger grade (table 5), chemical compound (Ia) has improved the motor function damage in crossbeam walking test (table 6) and the footprint test (table 7).
Table 5: chemical compound (Ia) is to the fractional influence of improved Tarlov/Klinger of Spinal Cord Injury in Rats
Improved Tarlov/Klinger mark
Medium (s.c.) (saline that comprises 30%DMSO) Chemical compound (Ia) 2mg/kg (s.c.)
The 2nd week 2.1±0.1 3.7±0.2*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with media pack
Table 6: chemical compound (Ia) is to the fractional influence of walking of the crossbeam of Spinal Cord Injury in Rats
Crossbeam walking mark
Medium (s.c.) (saline that comprises 30%DMSO) Chemical compound (Ia) 2mg/kg (s.c.)
The 2nd week 0.9±0.1 2.0±0.3*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with media pack
Table 7: chemical compound (Ia) is to the fractional influence of the footprint of Spinal Cord Injury in Rats
The footprint mark
Medium (s.c.) (saline that comprises 30%DMSO) Chemical compound (Ia) 2mg/kg (s.c.)
The 2nd week 1.7±0.4 3.6±0.3*
*: compare P＜0.05 (unidirectional variance analysis is carried out Newman-Kuels then and organized comparison test more) with media pack
Embodiment 5: chemical compound (Ia) combines with FKBP12, but different with fujimycin 506 be that it is not brought into play or performance immunosuppressive action seldom only
(1) with the test that combines of FKBP12
According to Tamura, the similar manner of K. etc. (Biochemical arid BiophysicalResearch Communications, Vol.202, No.1,437-499,1994) carries out in conjunction with test.The result lists in table 8.
(2) blended lymphocyte reaction (MLR)
The MLR test is carried out according to the similar manner of U.S. Pat 4929611.
The result lists in table 8.
Table 8: the pharmacological characteristics of chemical compound (Ia) and fujimycin 506 experiment in vitro
FKBP12 is in conjunction with IC 50(nM) MLR IC 50(nM)
Chemical compound (Ia) ＜5 ＞100
Fujimycin 506 ＜5 ＜2
Above conclusion show that chemical compound (Ia) does not have immunosuppressive activity, but it can with the FKBP12 combination.
Top result displayed explanation chemical compound (I) all has effective neurotrophic effect in the model in vitro and in vivo.In two cell culture models, chemical compound (I) even also increased the growth of neurite at low concentration.And, the functional rehabilitation after low dosage has quickened neural extruding infringement with the administration of chemical compound (I) whole body by the functional rehabilitation that increases sciatic neurite regeneration rate and promotion spinal cord injury.
In addition, as implied above, chemical compound (I) provides a kind of activity of the effectively neurotrophic or cell growth of exciting nerve, and still, it does not have immunosuppressive activity.Accordingly, the invention provides a kind of useful neurotrophic agents and be used for stimulating or promote neure growth or regeneration, particularly when a kind of immunosuppressive action when being disadvantageous or unwanted.
Others of the present invention comprise:
Goods, comprise packaging material and the top definite chemical compound (I) that is included in the described packaging material, wherein said chemical compound (I) is prevention or the treatment effective dose for the treatment of neuron dysfunction, and packaging material wherein comprise a label or written material, and this material points out that chemical compound (I) can maybe should be used for preventing or treatment neuronal damage/dysfunction.
A kind of commercial medicated bag comprises pharmaceutical composition and an incidental written material of containing the top chemical compound of determining (I), and wherein written material shows that chemical compound (I) can maybe should be used for preventing or treatment neuronal damage/dysfunction.
A kind of compositions for example comprises a kind of cell suspension with the cell handled of chemical compound (I), organizes or graft.These compositionss are used for repairing nervous system injury.These compositionss also can comprise other to the nerve growth stimulant, and for example the cell suspension of other type of promotion or auxiliary nervous cell growth for example produces myelinic cell such as schwann's cell or oligodendrocyte, neurogliocyte and sheath cell; Extracellular stroma ground substance is as collagen; Or other specific neuroregulator such as cytokine, factor,mitogenic, immune rabphilin Rab and neurotrophy material such as NGF-1, BDNF, CNTF, NT-3, NT-4 and NT-5.
Graft is autograft for example, and allograft or xenograft also can be handled to promote neure growth, as graft with as other application with chemical compound (I).
The ginseng person who introduces
Every piece of document that institute disclosed herein quotes or mentions, the content of patent application or patent disclosure all are that their full text is incorporated herein by reference.It also is that their full text is incorporated herein by reference that this application requires the content of any patent documentation of priority.Especially, U.S. Provisional Application No.60/258,500 content is incorporated herein by reference.
Revise and other embodiment
Obviously, all be possible according to above-mentioned instruction a large amount of modifications and variations of the present invention.Therefore should be appreciated that in the scope of appended claim, except other the content the present invention who clearly described also can implement herein.The various modifications and variations of described compositions and method and notion of the present invention are apparent to those skilled in the art under the condition that does not depart from scope and spirit of the present invention.Though described invention above, should be appreciated that invention required for protection is not to have a mind to be limited to these specific embodiments with particularly preferred embodiment.The various modifications that are used for implementing described pattern of the present invention are for medical science, and biology, chemistry or pharmacology subject or those skilled in the relevant art are conspicuous, are also included within the scope of the present invention.

Claims (11)

1. the application of following formula: compound in the preparation neurotrophic agents
Figure C018228860002C1
2. the application of claim 1, wherein neurotrophic agents is used for preventing or treatment neuronal damage/dysfunction.
3. the application of claim 1, wherein neurotrophic agents is used for stimulating or promotion nerve growth or regeneration.
4. the application of claim 1, wherein neurotrophic agents is used for promoting the functional rehabilitation of nerve injury.
5. the application of claim 2, wherein neuronal damage/dysfunction is a burn, wound, mechanical damage, surgical injury, physiology's damage, pathology damage or immunology damage cause.
6. the application of claim 2, wherein neuronal damage/dysfunction is a polymyositis, barre-Guillaian syndrome, Menetrier's disease, polyneuritis, mononeuritis, Alzheimer, parkinson, amyotrophic lateral sclerosis (ALS), hungtington's chorea, radiculopathy, diabetic neuropathy, the neuropathy that chemotherapy causes, alzheimer disease, vascular dementia, multiple sclerosis, health paralysis or spinal cord injury.
7. the application of claim 2, wherein neuronal damage/dysfunction is an Alzheimer, parkinson, amyotrophic lateral sclerosis, diabetic neuropathy, neuropathy that chemotherapy causes or spinal cord injury.
8. the application of claim 1, wherein chemical compound (I) is with the acceptable salt of its pharmacy, derivant, prodrug or solvate forms exist.
9. the application of claim 6, wherein neuronal damage/dysfunction is a diabetic neuropathy.
10. the application of claim 6, wherein neuronal damage/dysfunction is a spinal cord injury.
11. each application of claim 1 to 10, wherein chemical compound (I) is the chemical compound (Ia) of following formula:
Figure C018228860003C1
CNB018228860A 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs Expired - Fee Related CN1293877C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US60/258,500 2000-12-29

Publications (2)

Publication Number Publication Date
CN1538843A CN1538843A (en) 2004-10-20
CN1293877C true CN1293877C (en) 2007-01-10

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228860A Expired - Fee Related CN1293877C (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Country Status (18)

Country Link
EP (1) EP1353671A4 (en)
JP (1) JP2004527472A (en)
KR (2) KR20070030331A (en)
CN (1) CN1293877C (en)
AR (1) AR035411A1 (en)
AU (1) AU2002231277B2 (en)
BR (1) BR0116762A (en)
CA (1) CA2433384A1 (en)
CZ (1) CZ20032060A3 (en)
HU (1) HUP0302521A3 (en)
IL (1) IL156664A0 (en)
MX (1) MXPA03005941A (en)
NO (1) NO20032913D0 (en)
NZ (1) NZ527209A (en)
PL (1) PL366301A1 (en)
RU (1) RU2288716C2 (en)
WO (1) WO2002053159A1 (en)
ZA (1) ZA200305806B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (en) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd Therapeutic agent for spinal cord injury
JP5878015B2 (en) * 2008-07-23 2016-03-08 ノバルティス アーゲー Sphingosine monophosphate receptor modulators and their use to treat muscle inflammation
JP2015511242A (en) * 2012-02-23 2015-04-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） Calcineurin inhibitors for use in the treatment of pathological vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033458A (en) * 1987-12-09 1989-06-21 菲索斯有限公司 The method for preparing the immunosuppressor macrolide
WO1991004025A1 (en) * 1989-09-14 1991-04-04 Fisons Plc Novel macrocyclic compounds and novel method of treatment
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033458A (en) * 1987-12-09 1989-06-21 菲索斯有限公司 The method for preparing the immunosuppressor macrolide
WO1991004025A1 (en) * 1989-09-14 1991-04-04 Fisons Plc Novel macrocyclic compounds and novel method of treatment
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators

Also Published As

Publication number Publication date
AU2002231277B2 (en) 2006-11-30
IL156664A0 (en) 2004-01-04
ZA200305806B (en) 2005-01-26
EP1353671A4 (en) 2004-07-14
CN1538843A (en) 2004-10-20
HUP0302521A2 (en) 2003-11-28
KR20040007431A (en) 2004-01-24
CA2433384A1 (en) 2002-07-11
EP1353671A1 (en) 2003-10-22
JP2004527472A (en) 2004-09-09
MXPA03005941A (en) 2005-02-14
NO20032913D0 (en) 2003-06-24
NZ527209A (en) 2005-09-30
PL366301A1 (en) 2005-01-24
KR100794204B1 (en) 2008-01-14
WO2002053159A1 (en) 2002-07-11
AR035411A1 (en) 2004-05-26
CZ20032060A3 (en) 2004-01-14
BR0116762A (en) 2004-08-10
RU2288716C2 (en) 2006-12-10
HUP0302521A3 (en) 2007-03-28
KR20070030331A (en) 2007-03-15
RU2003123493A (en) 2005-01-20

Similar Documents

Publication Publication Date Title
Snyder Amphetamine psychosis: a" model" schizophrenia mediated by catecholamines
Yin et al. Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines
CN1732011A (en) Method of treatment for central nervous system injury
Schenk et al. Interactions between caffeine and cocaine in tests of self-administration
CN1592616A (en) GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity
Berridge et al. Super‐stereotypy II: Enhancement of a complex movement sequence by intraventricular dopamine D1 agonists
CN1293877C (en) Neurotrophic tacrolimus analogs
KR20210009422A (en) Methods and compositions for treating and/or preventing the progression and/or expression of age-related neurodegeneration
CN1794999A (en) Remedy for nerve damage
Miller et al. Vestibular-induced vomiting after vestibulocerebellar lesions
JPS60252416A (en) Cdp choline composition
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
CN1535150A (en) Novel use of 2-[5-(40fluorophenyl)3-pyridylmethylaminomethyl]
US20040077676A1 (en) Neurotrophic tacrolimus analogs
JP2009504636A (en) Pharmaceutical composition for treatment of nerve injury comprising plasma or serum
CN1346278A (en) Regulation of anaesthesia
RU2496511C1 (en) Pharmaceutical composition, agent (versions) and method of preventing and treating arthritis, osteoarthrosis and vertebral osteochondrosis (versions)
EP3362059B1 (en) New combination therapies for treating neurological damage
Hasan et al. The short-acting anesthetic propofol produces biphasic effects—depression and withdrawal rebound overshoot—on some (but not all) limbic evoked potentials in the behaving rat
Bloom et al. Behavioral effects of chronic melatonin and pregnenolone injections in a myelin mutant rat (taiep)
RU2351021C1 (en) Method of experimental pseudorheumatism modelling
Mavrogianni et al. Safety and reproductive safety of moxidectin in goats
CN104257658B (en) Sinomenine application in preparation treatment chronic pain companion's Depressive behavior medicine
CN1301570A (en) Use of nerve growth factor in curing organic solvent toxic peripheral neuropathy
CN1883491A (en) Medical use of ginsenoside Rh 1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060428

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060428

Address after: Tokyo, Japan

Applicant after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Applicant before: Fujisawa Pharmaceutical Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070110

Termination date: 20100201